BioCentury
ARTICLE | Company News

Bayer sales and marketing update

June 15, 2015 7:00 AM UTC

The U.K.’s NICE issued draft guidance recommending Xofigo radium-223 dichloride from Bayer to treat adults with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastases who have received treatment with docetaxel. The committee recommended the drug only when Bayer provides it at an undisclosed discount under a patient access scheme.

NICE previously recommended against Xofigo to treat patients with CRPC, symptomatic bone metastases and no known visceral metastases -- its approved indication in the EU. In a March 2014 preliminary appraisal, the committee said Bayer did not provide data comparing Xofigo to the appropriate treatments, including docetaxel as first-line treatment for CRPC and Zytiga abiraterone as second-line treatment (see BioCentury, March 31, 2014). ...